Study #2022-0374
Phase I trial of Adagrasib (MRTX849) in combination with Cetuximab and Irinotecan in patients with colorectal cancer.
MD Anderson Study Status
Not Accepting
Treatment Agent
MRTX849, Irinotecan, Cetuximab
Description
To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colon Cancer, Colorectal Cancer
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-794-1615
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.